Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Celgene International Sàrl
Woman and Man Max 99 years
Celgene International Sàrl
Update Il y a 4 ans
A clinical study to compare the effectiveness and safety of the combination of lenalidomide, melphalan and prednisone with placebo, melphalan and prednisone in newly diagnosed Multiple Myeloma patients who are 65 years or older
To determine the efficacy of lenalidomide plus melphalan and prednisone (MPR) compared to placebo plus melphalan and prednisone (MP) in subjects with newly diagnosed multiple myeloma (MM) who are 65 y...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Celgene International Sàrl
Update Il y a 4 ans
A MULTICENTER, SINGLE-ARM, OPEN-LABEL EXPANDED ACCESS PROGRAM FOR LENALIDOMIDE PLUS DEXAMETHASONE IN PREVIOUSLY TREATED SUBJECTS WITH MULTIPLE MYELOMA
To determine the time to progression (TTP) of previously treated subjects with multiple myeloma receiving lenalidomide
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Celgene International Sàrl
Update Il y a 4 ans
A multicenter, single-arm, open-label safety study of lenalidomide plus dexamethasone in previously treated subjects with Multiple Myeloma
To provide lenalidomide to subjects with a high likelihood of benefit.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Celgene International Sàrl
Update Il y a 4 ans
A PHASE II, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SINGLE-AGENT LENALIDOMIDE (REVLIMID®) IN SUBJECTS WITH RELAPSED OR REFRACTORY T-CELL NON-HODGKIN’S LYMPHOMA
•To determine the efficacy of lenalidomide monotherapy in relapsed or refractory T-cell NHL. Efficacy will be assessed by measuring the response rate, tumor control rate, duration of response, time t...
Country
None
organs
None
Specialty
None
Closed trial
More information